S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Could This Be The Biggest Stock Of 2023? (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Could This Be The Biggest Stock Of 2023? (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Could This Be The Biggest Stock Of 2023? (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Could This Be The Biggest Stock Of 2023? (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:HUGE

FSD Pharma - HUGE Stock Forecast, Price & News

$1.45
-0.11 (-7.05%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.39
▼
$1.58
50-Day Range
$0.94
▼
$1.81
52-Week Range
$0.62
▼
$1.88
Volume
81,786 shs
Average Volume
171,490 shs
Market Capitalization
$55.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

HUGE stock logo

About FSD Pharma (NASDAQ:HUGE) Stock

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Receive HUGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter.

HUGE Stock News Headlines

March 22, 2023 | marketwatch.com
FSD Pharma Gets Green Light for Depression-Drug Clinical Trial in Australia
March 22, 2023 | finance.yahoo.com
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
March 24, 2023 | Upexi, Inc (Ad)
Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!pixel
March 14, 2023 | msn.com
Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock
March 14, 2023 | finance.yahoo.com
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock
March 1, 2023 | finance.yahoo.com
InvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory Board
February 28, 2023 | benzinga.com
Shark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics Company
February 28, 2023 | finance.yahoo.com
Original "Shark" and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
March 24, 2023 | Upexi, Inc (Ad)
Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!pixel
February 14, 2023 | finance.yahoo.com
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
February 13, 2023 | baystreet.ca
Allied, FSD, Magnet at 52-Week Highs
February 9, 2023 | finance.yahoo.com
InvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS
February 7, 2023 | finance.yahoo.com
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
February 3, 2023 | theglobeandmail.com
FSD Pharma breaks out of its trading range after insiders bet on company prospects
January 30, 2023 | proactiveinvestors.com
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS
January 30, 2023 | wsj.com
Recruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
January 19, 2023 | finance.yahoo.com
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
January 13, 2023 | proactiveinvestors.com
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves
January 12, 2023 | morningstar.com
FSD Pharma Inc Ordinary Shares - Class B (Sub Voting) HUGE Stock Quote
November 29, 2022 | proactiveinvestors.com
FSD Pharma announces changes to its board of directors
November 28, 2022 | finance.yahoo.com
FSD Pharma Announces Changes to the Board of Directors
November 15, 2022 | finance.yahoo.com
InvestmentPitch Media Video Discusses FSD Pharma’s Announcement that the Claim for US$30.2 Million Brought by Dr. Raza Bokhari, the Company’s Former CEO, has been Dismissed in its Entirety
November 10, 2022 | finance.yahoo.com
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari
October 1, 2022 | seekingalpha.com
HUGE FSD Pharma Inc.
September 12, 2022 | finance.yahoo.com
FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available
September 6, 2022 | proactiveinvestors.com
FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder
July 13, 2022 | finance.yahoo.com
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium
See More Headlines
Receive HUGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter.

HUGE Company Calendar

Today
3/23/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HUGE
CUSIP
N/A
CIK
1771885
Web
fsdpharma.com
Phone
(416) 854-8884
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,280,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-59.50%
Return on Assets
-50.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.41
Quick Ratio
3.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.34 per share
Price / Book
1.08

Miscellaneous

Outstanding Shares
38,100,000
Free Float
34,854,000
Market Cap
$55.25 million
Optionable
Optionable
Beta
0.61

Key Executives

  • Anthony J. Durkacz
    Executive Co-Chairman & Chief Executive Officer
  • Zeeshan Saeed
    Executive Co-Chairman & President
  • Donal Carroll
    Chief Operating Officer & Director
  • Nathan Coyle
    Chief Financial Officer & Controller
  • Sandy Huard
    Head-Investor Relations & Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













HUGE Stock - Frequently Asked Questions

How have HUGE shares performed in 2023?

FSD Pharma's stock was trading at $0.7884 on January 1st, 2023. Since then, HUGE shares have increased by 83.9% and is now trading at $1.45.
View the best growth stocks for 2023 here.

Are investors shorting FSD Pharma?

FSD Pharma saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 456,800 shares, an increase of 37.4% from the February 13th total of 332,500 shares. Based on an average daily trading volume, of 149,200 shares, the days-to-cover ratio is presently 3.1 days. Currently, 2.8% of the shares of the stock are sold short.
View FSD Pharma's Short Interest.

When is FSD Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our HUGE earnings forecast.

What other stocks do shareholders of FSD Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Assertio (ASRT), Bionano Genomics (BNGO), Ideanomics (IDEX), Stealth BioTherapeutics (MITO), Millendo Therapeutics (MLND), 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB).

What is FSD Pharma's stock symbol?

FSD Pharma trades on the NASDAQ under the ticker symbol "HUGE."

Who are FSD Pharma's major shareholders?

FSD Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.14%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of FSD Pharma?

Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FSD Pharma's stock price today?

One share of HUGE stock can currently be purchased for approximately $1.45.

How much money does FSD Pharma make?

FSD Pharma (NASDAQ:HUGE) has a market capitalization of $55.25 million.

How can I contact FSD Pharma?

FSD Pharma's mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The official website for the company is fsdpharma.com. The company can be reached via phone at (416) 854-8884 or via email at ir@fsdpharma.com.

This page (NASDAQ:HUGE) was last updated on 3/24/2023 by MarketBeat.com Staff